Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5730223 | 0.91 | SLC2A1 (0.40) | PTGS1THRATHRBHSP90AA1KCNH2 | |
| SCHEMBL5729608 | 0.83 | STAT3 (0.48) | ESR1ESR2MEN1ALDH1A1KMT2A | |
| SCHEMBL5729515 | 0.83 | APP (0.44) | ESR1ESR2ALDH1A1STAT3 | |
| SCHEMBL5728792 | 0.82 | PTGS1 (0.48) | PTGS1ESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL5743851 | 0.80 | MCHR1 (0.41) | PTGS1MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL5730021 | 0.78 | KMT2A (0.46) | PTGS1HSP90AA1ESR1ESR2MEN1 | |
| SCHEMBL5728503 | 0.76 | ESR1 (0.50) | ESR1ESR2 | |
| SCHEMBL5730104 | 0.76 | ESR1 (0.50) | THRATHRBESR1ALDH1A1STAT3 | |
| SCHEMBL5728694 | 0.76 | MAPK1 (0.53) | PTGS1MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5729665 | 0.75 | APP (0.55) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102755-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008001-A1 | SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS1 588/4885THRA 219/4885THRB 394/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS1 588/4885THRA 219/4885THRB 394/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | PTGS1 413/4885THRA 585/4885THRB 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.